Cargando…

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine

Amphiphilic polymers (HA-ANI) were prepared by grafting hyaluronic acid (HA) and 6-(2-nitroimidazole)hexylamine (ANI) and then self-assemble in water to form nanoparticles (NPs) that could be loaded with paclitaxel (PTX) and gemcitabine (GEM) by dialysis. Infrared spectroscopy and (1)H-NMR indicated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fan, Fan, Zehui, Zhang, Lixia, He, Yanjuan, Hu, Run, Xiang, Jinkun, Fu, Shiyang, Wang, Guowei, Wang, Jianlong, Tao, Xiaojun, Zhang, Pan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513990/ https://www.ncbi.nlm.nih.gov/pubmed/37735318 http://dx.doi.org/10.1186/s11671-023-03899-1

Ejemplares similares

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
por: Liu, Yarong, et al.
Publicado: (2014)

Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
por: Xin, Xiaofei, et al.
Publicado: (2020)

Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation
por: Levit, Shani L., et al.
Publicado: (2020)

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer
por: Guo, Beibei, et al.
Publicado: (2023)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy
por: Devulapally, Rammohan, et al.
Publicado: (2015)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
por: Wang, Biyun, et al.
Publicado: (2022)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
por: Montero, Alberto, et al.
Publicado: (2012)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention
por: Wang, Hongkun, et al.
Publicado: (2020)

Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells
por: Tao, Liu, et al.
Publicado: (2018)

A Modular Coassembly Approach to All-In-One Multifunctional Nanoplatform for Synergistic Codelivery of Doxorubicin and Curcumin
por: Yang, Muyang, et al.
Publicado: (2018)

Gemcitabine/paclitaxel: Interstitial pneumonia: case report
Publicado: (2021)

Codelivery of DOX and siRNA by folate-biotin-quaternized starch nanoparticles for promoting synergistic suppression of human lung cancer cells
por: Li, Liangping, et al.
Publicado: (2019)

Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects
por: Jiang, Hong, et al.
Publicado: (2019)

Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy
por: Jin, Xun, et al.
Publicado: (2016)

Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles
por: Chen, Li, et al.
Publicado: (2013)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
por: Comella, P, et al.
Publicado: (2004)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
por: Zhang, Feng, et al.
Publicado: (2022)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2021)

Nucleus-selective codelivery of proteins and drugs for synergistic antitumor therapy
por: Yang, Lan, et al.
Publicado: (2022)

Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
por: Zhang, Zheng, et al.
Publicado: (2021)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
por: Ou, Junwen, et al.
Publicado: (2020)

Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers
por: Kumar, Girish, et al.
Publicado: (2023)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2015)

Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells
por: Chen, Li, et al.
Publicado: (2023)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_37ofmgf9q70oi9uf5grjctfunu